Novel VIM Metallo-β-Lactamase Variant from Clinical Isolates of Enterobacteriaceae from Algeria

Antimicrobial Agents and Chemotherapy
2010.0

Abstract

Five different strains of bacteria belonging to the family Enterobacteriaceae were isolated from two patients hospitalized in the intensive care unit of the Central Military Hospital of Algiers, Algeria. All five strains, one Providencia stuartii strain, two Escherichia coli strains, and two Klebsiella pneumoniae strains, were intermediate or resistant to all beta-lactams, including carbapenems. Synergy between imipenem and EDTA was observed for all five strains. The results of the PCR experiment confirmed the presence of a bla(VIM) gene in all five strains. The bla(VIM) genes were located as part of a class 1 integron on a 180-kb conjugative plasmid. They encoded a novel metallo-beta-lactamase designated VIM-19, which differed from the parental enzyme VIM-1 by only two substitutions: Ser228Arg, previously observed in the closely related enzyme VIM-4, and Asn215Lys, not previously observed in other VIM-type carbapenemases. VIM-19 was further characterized after purification through determination of its kinetic constants. This enzyme was inhibited by EDTA and hydrolyzed penicillins, cephalosporins, and carbapenems, as observed for other VIM-type carbapenemases but with greater catalytic efficiency against penicillins than VIM-1. VIM-19 is the first carbapenemase enzyme identified from an isolate from Algeria. These results confirm the emergence of VIM-4-like enzymes in members of the family Enterobacteriaceae from Mediterranean countries.

Knowledge Graph

Similar Paper

Novel VIM Metallo-β-Lactamase Variant from Clinical Isolates of Enterobacteriaceae from Algeria
Antimicrobial Agents and Chemotherapy 2010.0
VIM-19, a Metallo-β-Lactamase with Increased Carbapenemase Activity from Escherichia coli and Klebsiella pneumoniae
Antimicrobial Agents and Chemotherapy 2010.0
Characterization of the New Metallo-β-Lactamase VIM-13 and Its Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in Spain
Antimicrobial Agents and Chemotherapy 2008.0
VIM-15 and VIM-16, Two New VIM-2-Like Metallo-β-Lactamases in Pseudomonas aeruginosa Isolates from Bulgaria and Germany
Antimicrobial Agents and Chemotherapy 2008.0
Carbapenem Resistance among Pseudomonas aeruginosa Strains from India: Evidence for Nationwide Endemicity of Multiple Metallo-β-Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly Characterized VIM-18)
Antimicrobial Agents and Chemotherapy 2009.0
Biochemical Characterization of Metallo-β-Lactamase VIM-11 from a Pseudomonas aeruginosa Clinical Strain
Antimicrobial Agents and Chemotherapy 2008.0
First Occurrence of an Escherichia coli Clinical Isolate Producing the VIM-1/VIM-2 Hybrid Metallo-β-Lactamase VIM-12
Antimicrobial Agents and Chemotherapy 2007.0
Outbreak of Acinetobacter baumannii with Chromosomally Encoded VIM-1 Undetectable by Imipenem-EDTA Synergy Tests
Antimicrobial Agents and Chemotherapy 2008.0
Molecular Epidemiology of Outbreak-Related Pseudomonas aeruginosa Strains Carrying the Novel Variant bla <sub>VIM-17</sub> Metallo-β-Lactamase Gene
Antimicrobial Agents and Chemotherapy 2009.0
Kinetic Characterization of VIM-7, a Divergent Member of the VIM Metallo-β-Lactamase Family
Antimicrobial Agents and Chemotherapy 2008.0